Saturday, October 3, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· January 27, 2026

Star Equity (STRR) Q3 2025 Earnings Transcript

View original at finance.yahoo.com
Star Equity (STRR) Q3 2025 Earnings Transcript Image source: The Motley Fool. DATE Thursday, November 13, 2025 at 10 a.m…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Star Equity stock is undervalued

    80% confidence
  • RPO market is bouncing along bottom with gradual return to normal attrition

    80% confidence
  • Energy Services growth opportunities are outsized versus larger competitors

    80% confidence
  • 2022 baseline of $100M gross profit and $20M EBITDA (20% margin) is considered mid-cycle normalized for Business Services

    80% confidence
  • Target synergies of $2M annually will be fully realized within 6 months (by mid-2026)

    80% confidence
  • Gyrodyne plans to complete liquidation of real estate assets by end of 2027

    80% confidence
  • Exploring partnership with private equity or growth capital for AI/digital investments in Business Services, with high probability eventually (multiple quarters out)

    80% confidence
  • Jeffrey Eberwein has been buying shares at higher prices than current $9 range

    80% confidence
  • Gyrodyne is trading 50-60% below stated NAV

    80% confidence
  • Target 30% incremental margin at scale for Business Services segment

    80% confidence
  • Building Solutions targets mid-20% gross margin

    80% confidence
  • Corporate costs will reduce from $2.6M/quarter to ~$2M/quarter run rate ($8M annually)

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com